This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year.

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Photo: Christophe Gateau/dpa (Photo by Christophe Gateau/picture alliance via Getty Images) ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...

Researchers from the Department of Energy's Quantum Science Center (QSC) headquartered at Oak Ridge National Laboratory (ORNL) have achieved a significant milestone by demonstrating the first digital ...

Abstract: This study conducts a one-dimensional steady- state hydraulic analysis of CSU Creek using HEC-RAS to evaluate the effectiveness of a flood control structure proposed by the Department of ...

PARIS — RAS Luxury Skincare, the Indian farm-to-face brand, closed a 65 Crores, or $7.5 million, Series B funding round led by Dabur Ventures. Dabur Ventures is the venture arm of the largest ...

Spinal deformities such as scoliosis and kyphosis are among the most serious complications of neurofibromatosis type 1 (NF1), a genetic disorder that affects about one in 3,000 people. These ...

Bain Capital agreed to sell its data centers in China to Shenzhen Dongyangguang Industry Co. in a transaction valued at about $4 billion. Shenzhen Dongyangguang, the parent of Shanghai-listed ...

Third-party model portfolios had $646 billion in assets under advisement as of March 31, 2025—an increase of 62% since Morningstar last surveyed for assets in June 2023, less than two years ago.

Forbes contributors publish independent expert analyses and insights. I write about the economics of AI. The AI boom has been defined by unprecedented innovation across nearly every sector. From ...

KRASG12C-targeted therapies like sotorasib and adagrasib have been approved, but resistance challenges persist, necessitating further research into RAS(ON) therapies. Revolution Medicines is ...